Summary & Overview

Major Gastrointestinal Disorders and Peritoneal Infections without CC/MCC: Inpatient Reimbursement Overview

DRG 373 encompasses major gastrointestinal disorders and peritoneal infections without Complication or Comorbidity or Major Complication or Comorbidity, covering serious intra-abdominal conditions that do not meet higher severity criteria. This matters for inpatient reimbursement because Diagnosis-Related Group assignment drives Medicare payment by reflecting the expected resource intensity for these noncomplicated but significant clinical scenarios.

Major Gastrointestinal Disorders and Peritoneal Infections without CC/MCCDRG 373Diagnosis-Related GroupInpatient ReimbursementMedicareGeneral SurgeryInfectious DiseaseGastroenterologyHospital CodingCase Mix

DRG 373 Overview

DRG 373 covers major gastrointestinal disorders and peritoneal infections without Complication or Comorbidity or Major Complication or Comorbidity. This group includes cases such as noncomplicated gastrointestinal perforations, severe infections of the peritoneum without additional coded complications, and other significant intra-abdominal conditions that do not meet higher severity tiers. It matters for Medicare reimbursement because it establishes the inpatient payment relative to resource use for these serious but noncomplicated presentations. Accurate coding and documentation determine assignment to this Diagnosis-Related Group and the associated payment weight.

Clinical Trials

Acute surgical intervention trials: randomized or pragmatic studies comparing timing, technique, or perioperative protocols for patients presenting with acute major gastrointestinal disorders (such as complicated diverticulitis, perforated viscus, or severe intra-abdominal infections) who require urgent operative or interventional management. These studies enroll hospitalized adults at the time of acute presentation and evaluate outcomes like time to source control, complication rates, length of stay, and short-term mortality. Findings inform surgeons and hospitalists about best practices to reduce in-hospital morbidity, optimize resource use, and potentially shorten costly inpatient stays for DRG 373 patients.
Comparative effectiveness studies of nonoperative versus operative management in complicated GI disease: observational cohorts or randomized trials assessing conservative medical therapy (antibiotics, drainage, bowel rest) versus early surgery for subsets of major GI disorders without major comorbid complications. These studies focus on patients stable enough for trial enrollment but at risk for progression, measuring readmission rates, need for delayed surgery, health resource utilization, and patient-centered outcomes such as functional recovery. Results help payers and clinicians determine which pathways reduce total cost of care and unnecessary procedures while maintaining safe outcomes for this DRG population.
Post-discharge outcomes and care-transition research: longitudinal studies and quality-improvement trials that follow patients discharged after hospitalization for major GI disorders and peritoneal infections to evaluate readmissions, post-acute care needs, outpatient complication surveillance, and adherence to secondary prevention strategies. Populations include medical and surgical survivors from index admissions, with emphasis on identifying predictors of early readmission and tailoring follow-up intensity (e.g., early clinic visits, home health, or targeted education). This research is relevant for hospitals and payers seeking to lower 30-day readmission penalties, allocate post-acute services efficiently, and improve long-term functional outcomes for patients classified under DRG 373.

Related Codes

374-DIGESTIVE-MALIGNANCY-WITH-MCC

Digestive Malignancy with Major Complication or Comorbidity: Inpatient Reimbursement Overview

368-MAJOR-ESOPHAGEAL-DISORDERS-WITH-MCC

Major Esophageal Disorders with MCC: Inpatient Reimbursement Overview

378-GASTROINTESTINAL-HEMORRHAGE-WITH-CC

Gastrointestinal Hemorrhage with CC: Inpatient Reimbursement Overview

392-ESOPHAGITIS-GASTROENTERITIS-AND-MISCELLANEOUS-DIGESTIVE-DISORDERS-WITHOUT-MCC

Esophagitis, Gastroenteritis and Miscellaneous Digestive Disorders: Inpatient Reimbursement Overview

394-OTHER-DIGESTIVE-SYSTEM-DIAGNOSES-WITH-CC

Other Digestive System Diagnoses with CC: Inpatient Reimbursement Overview

393-OTHER-DIGESTIVE-SYSTEM-DIAGNOSES-WITH-MCC

Other Digestive System Diagnoses with MCC: Inpatient Reimbursement Overview

398-APPENDIX-PROCEDURES-WITH-CC

Appendix Procedures with CC: Inpatient Reimbursement Overview

345-MINOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITH-CC

Minor Small and Large Bowel Procedures with CC: Inpatient Reimbursement Overview

388-GASTROINTESTINAL-OBSTRUCTION-WITH-MCC

Gastrointestinal Obstruction with MCC: Inpatient Reimbursement Overview

351-INGUINAL-AND-FEMORAL-HERNIA-PROCEDURES-WITH-CC

Inguinal and Femoral Hernia Procedures with CC: Inpatient Reimbursement Overview

Showing 1–10 of 57

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.